Loading organizations...
Ajax Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, and New York City that develops targeted small-molecule therapies and next-generation Type II JAK2 inhibitors for the treatment of blood cancers. The firm utilizes computational chemistry and structure-based technologies to target cytokine signaling pathways driving hematologic malignancies, focusing on myeloproliferative neoplasms such as myelofibrosis. Operating as a pre-commercial entity, the enterprise has raised over $135 million in total capital, including a $95 million Series C financing round secured in May 2024 to advance its lead asset into Phase 1 clinical trials. This clinical advancement is supported by a syndicate of prominent investors and strategic partners, including Eli Lilly and Company, EcoR1 Capital, Goldman Sachs Alternatives, and Schrödinger, Inc. Ajax Therapeutics was founded in 2019 by Martin Vogelbaum, Ross Levine, and Olli Silvennoinen.
Ajax Therapeutics has raised $135.0M across 2 funding rounds.
Ajax Therapeutics has raised $135.0M in total across 2 funding rounds.
Ajax Therapeutics has raised $135.0M in total across 2 funding rounds.
Ajax Therapeutics's investors include Ming Cheah, Boxer Capital, EcoR1 Capital, Eli Lilly and Company, Inning One Ventures, Point72, RA Capital Management, Schr"dinger, Vivo Capital, Scott Platshon, Martin Vogelbaum, Ross Levine.
Ajax Therapeutics has raised $135.0M across 2 funding rounds. Most recently, it raised $95.0M Series C in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 13, 2024 | $95M Series C | Ming Cheah | Boxer Capital, EcoR1 Capital, ELI Lilly And Company, Inning ONE Ventures, Point72, RA Capital Management, Schr"dinger, Vivo Capital | Announced |
| Jun 1, 2021 | $40M Venture Round | Scott Platshon | Boxer Capital, Martin Vogelbaum, Ross Levine, NYU Langone Health, Ramy Farid | Announced |
